Delgocitinib Brand names: Anzupgo

What is delgocitinib used for?

From the label: indications and usage

ANZUPGO is indicated for the topical treatment of moderate to severe chronic hand eczema (CHE) in adults who have had an inadequate response to, or for whom topical corticosteroids are not advisable. Limitations of Use Use of ANZUPGO in combination with other JAK inhibitors or potent immunosuppressants is not recommended. ANZUPGO is a Janus kinase (JAK) inhibitor indicated for the topical treatment of moderate to severe chronic hand eczema (CHE) in adults who have had an inadequate response to, or for whom topical corticosteroids are not advisable. ( 1 ) Limitations of Use: Use of ANZUPGO in combination with other JAK inhibitors or potent immunosuppressants is not recommended.

Conditions named in the indications of delgocitinib's FDA labels, with every medicine labeled for each:

• Eczema (atopic dermatitis)

FDA pharmacologic class: Janus Kinase Inhibitor.

What does the patient leaflet for delgocitinib say first?

The FDA-approved Medication Guide or Patient Information that comes with the medicine, in its own words.

From the patient leaflet: What is the most important information I should know about ANZUPGO?

ANZUPGO may cause serious side effects, including: Serious Infections. ANZUPGO may increase your risk of infections. ANZUPGO contains delgocitinib. Delgocitinib belongs to a class of medicines called Janus kinase (JAK) inhibitors. JAK inhibitors are medicines that affect your immune system. JAK inhibitors can lower the ability of your immune system to fight infections. Some people have had serious infections while taking JAK inhibitors by mouth or applying on the skin, including tuberculosis (TB), and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have been hospitalized or died from these infections. ANZUPGO should not be used in people with an active, serious infection. You should not start using ANZUPGO if you have any kind of infection unless your healthcare provider tells you it is okay. You may be at a higher risk of developing shingles (herpes zoster) or eczema herpeticum (a blistery, painful skin rash) during treatment with ANZUPGO. Before starting ANZUPGO, tell your healthcare provider if you: are being treated for an infection have an infection that does not go away or that keeps coming back have TB or have been in close contact with someone with TB have had shingles (herpes zoster) have had hepatitis B or C think you have an infection or have symptoms of an infection such as: fever, sweating, or chills muscle aches cough or shortness of breath blood in your phlegm weight loss warm, red, or painful skin or sores on your body diarrhea or stomach pain burning when you urinate or urinating more often than usual feeling very tired After starting ANZUPGO, call your healthcare provider right away if you have any symptoms of an infection. […]

From the patient leaflet: How should I store ANZUPGO?

Store ANZUPGO at room temperature between 68°F to 77°F (20°C to 25°C). Do not freeze ANZUPGO. Keep ANZUPGO and all medicines out of the reach of children.

Is there a generic for delgocitinib (Anzupgo)?

No generic delgocitinib is approved (Drugs@FDA, October 8, 2026).

The Orange Book lists 1 patent for Anzupgo cream: the compound patent runs to September 19, 2031. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.

What does the delgocitinib label say about other medicines?

The delgocitinib label names 1 other medicine in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.

Check delgocitinib against other medicines

What do FAERS reports show for delgocitinib?

The FDA Adverse Event Reporting System holds 233 reports that list delgocitinib among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 2 are coded as a death and 35 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.

The most reported reactions

• Product Use In Unapproved Indication (a use or a product term, not a reaction)56
• Pruritus (named in the label)26
• Dermatitis Atopic25
• Dermatitis20
• Erythema (named in the label)20
• Drug Ineffective (a use or a product term, not a reaction)18
• Rash14
• Eczema (a use or a product term, not a reaction)11

Side effects: the label's list and every FAERS reaction

What else is labeled for the same conditions as delgocitinib?

6 other medicines are given the same way (topical) and in the same FDA class as delgocitinib or labeled mainly for the same use (eczema (atopic dermatitis)), the same class first. Eczema (atopic dermatitis) lists all 26 medicines labeled for it, by any route. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.

Every medicine labeled for the same conditions as delgocitinib

What next?

Alternatives to delgocitinib

6 medicines for the same use

Other janus kinase inhibitors

the pharmacologic class, with prices and generics

Delgocitinib side effects

the label's list beside FAERS reports

Check an interaction

what two or more labels say about each other